Motus GI Holdings, Inc. Price & Performance (MOTS)

Motus GI Holdings has initiated liquidation and dissolution proceedings following its board’s review of strategic options, after determining it cannot maintain a Nasdaq listing. The company’s share price has plummeted nearly 100% over the past year, and it reported a net loss of $16.1 million for the last twelve months.12

Orchestra BioMed posted a net loss of $61 million in 2024, up from $49.1 million a year prior, as research and development expenses rose 27%. Revenue slipped to $2.6 million, largely due to lower partnership income, while cash reserves stand at $66.8 million, covering roughly 16 months of operations.34

Tandem Diabetes Care has recently received a consensus "Moderate Buy" rating from analysts, with eight recommending a hold and eleven suggesting a buy. The company’s stock has experienced notable volatility, reflecting ongoing uncertainty in the medical device sector and fluctuating investor sentiment.5